Trexquant Investment LP Has $3.73 Million Stock Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

Trexquant Investment LP lifted its stake in Ascendis Pharma A/S (NASDAQ:ASND) by 235.9% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 27,067 shares of the biotechnology company’s stock after purchasing an additional 19,010 shares during the quarter. Trexquant Investment LP’s holdings in Ascendis Pharma A/S were worth $3,726,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of ASND. Rice Hall James & Associates LLC lifted its stake in Ascendis Pharma A/S by 2.0% during the fourth quarter. Rice Hall James & Associates LLC now owns 163,888 shares of the biotechnology company’s stock valued at $22,562,000 after buying an additional 3,274 shares in the last quarter. Nomura Asset Management Co. Ltd. raised its holdings in shares of Ascendis Pharma A/S by 42.5% during the third quarter. Nomura Asset Management Co. Ltd. now owns 18,000 shares of the biotechnology company’s stock valued at $2,688,000 after acquiring an additional 5,371 shares during the period. Exome Asset Management LLC lifted its position in shares of Ascendis Pharma A/S by 119.2% in the 3rd quarter. Exome Asset Management LLC now owns 43,849 shares of the biotechnology company’s stock valued at $6,547,000 after acquiring an additional 23,849 shares in the last quarter. abrdn plc lifted its position in shares of Ascendis Pharma A/S by 18.3% in the 4th quarter. abrdn plc now owns 187,180 shares of the biotechnology company’s stock valued at $25,769,000 after acquiring an additional 28,967 shares in the last quarter. Finally, GAMMA Investing LLC boosted its stake in Ascendis Pharma A/S by 58.0% in the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 214 shares during the period.

Ascendis Pharma A/S Stock Down 4.9 %

Shares of ASND opened at $142.67 on Monday. The firm has a market cap of $8.66 billion, a price-to-earnings ratio of -20.09 and a beta of 0.61. The company’s fifty day moving average is $146.39 and its 200-day moving average is $137.93. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $169.37.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($1.32) by $0.64. As a group, research analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ASND has been the topic of several recent analyst reports. JPMorgan Chase & Co. boosted their target price on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the company an “overweight” rating in a research note on Tuesday, March 18th. Cantor Fitzgerald increased their price objective on Ascendis Pharma A/S from $170.00 to $200.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 25th. The Goldman Sachs Group lifted their target price on Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a “buy” rating in a research note on Thursday, February 13th. UBS Group started coverage on shares of Ascendis Pharma A/S in a research report on Tuesday, January 7th. They issued a “buy” rating and a $196.00 price target for the company. Finally, Morgan Stanley set a $180.00 price target on shares of Ascendis Pharma A/S in a report on Tuesday, February 18th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $204.64.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.